Anagre Cap. in Patients With High-Risk Essential Thrombocythemia

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 5, 2017

Primary Completion Date

December 5, 2020

Study Completion Date

December 5, 2020

Conditions
Essential Thrombocythemia
Interventions
DRUG

Anagre Cap.

from 0.5mg twice a day to maximally increase total10mg in 8 weeks and maintain maximal tolerable dose to 104 weeks

Trial Locations (21)

Unknown

National Health Insurance Service Ilsan Hospital, Goyang-si

The Catholic University of Korea. ST. Vincents Hospital, Suwon

Hallym UNIV. Medical Center, Anyang

Daegu Catholic University Medical Center, Daegu

Keimyung University Dongsan Medical Center, Daegu

Kyungpook national university hospital, Daegu

Dongguk University Medical Center, Goyang

Cheonnam National University Hwasun Hospital, Hwasun

Gachon University Gil Medical Center, Incheon

Inha University Hospital, Incheon

Jeju National University Hospital, Jeju City

Pusan National University Hospital, Pusan

Ewha Wonans University Mokdong Hospital, Seoul

Hallym UNIV. Medical Center, Seoul

Inje University Sanggye Paik Hospital, Seoul

Korea University Anam Hospital, Seoul

Seoul National University Hospital, Seoul

SMG - SNU Boramae Medical Center, Seoul

Soon Chun Hyang University Hospital Seoul, Seoul

Veterans Health Service medical Center, Seoul

Yonsei University Health System, SEVERANCE HOSPITAL, Seoul

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT03232177 - Anagre Cap. in Patients With High-Risk Essential Thrombocythemia | Biotech Hunter | Biotech Hunter